Figure 3.

VV.CXCL11 administration into tumor-bearing mice led to robust CXCL11 generation, and tumor control. Wild type C57 Bl/6 mice were subcutaneously inoculated with TC1 murine lung cancer cells on the right flanks, and when tumors were established (approximately 200 mm³), they were treated with 10⁸ pfu of VV.luc and VV.CXCL11, administered intravenously. A) Tumors were then monitored for the following 10–14 days. Data shown are means ± SEM, n = 5 mice per group. Tumors treated with both VV's were significantly smaller than control tumors (p < 0.05) but not different from one another. B) At Day 25, mice were euthanized, and tumors were excised for ex vivo analysis. Flow cytometry indicated a significant (** = p < 0.01) influx of CD8 tumor-infiltrating lymphocytes (TILs) in the VV.CXCL11-treated mice. C) Tumor tissues were processed and analyzed for CXCL11 production via ELISA. Values are reported in nanogram CXCL11 detected per gram of tumor tissue. CXCL11 levels were significantly (** = p < 0.01) higher in the VV.CXCL11 treated mice. D) The presence of other cytokines were also evaluated by ELISA to assess the specificity of CXCL11 production, and others that may be induced in this model. Values are reported in picogram of cytokines detected per gram of tumor tissue. There were no significant differences.